| 柳侠平,苏林红,欧阳钦.非诺贝特联合熊去氧胆酸治疗熊去氧胆酸应答不佳PBC 的疗效观察[J].浙江中西医结合杂志,2019,29(4): |
| 非诺贝特联合熊去氧胆酸治疗熊去氧胆酸应答不佳PBC 的疗效观察 |
| Research on Effect of Fenofibrate Combined with Ursodeoxy- cholic Acid in the Treatment of Poor Response to Ursodeoxy- cholic Acid in Primary Biliary CholangitisLiu Xiaping1,Su linhong1,Zhu Xiaoqu1. (1. Wenzhou Hospital of Traditional Chinese Medicine,Zhejiang ,Wenzhou 325000) |
| 投稿时间：2018-08-13 修订日期：2018-10-15 |
| DOI： |
| 中文关键词: 原发性胆汁性胆管炎 非诺贝特 熊去氧胆酸 应答不佳 疗效 |
| 英文关键词:primary biliary cholangitis Ursodeoxycholic Acid Poor Response to Fenofibrate Effect |
| 基金项目:温州市卫计委课题,编号2017B08 |
|
| 摘要点击次数: 830 |
| 全文下载次数: 3 |
| 中文摘要: |
| ［］ 目的：观察非诺贝特联合熊去氧胆酸(UDCA)治疗UDCA应答不佳原发性胆汁性胆管炎(PBC)的临床疗效。方法：选取2016年3月至2018年2月我院收治的UDCA应答不佳的PBC患者30例,均为肝硬化代偿期,随机分成治疗组15例,对照组15例。对照组给予UDCA,15mg/(kg.d),分2～3次口服,治疗组UDCA基础上联合非诺贝特,0.16 g/d,口服。6个月为一个疗程。观察并记录患者治疗前及治疗6个月后的实验室指标如ALT、AST、ALP、ALB、TBIL、IgM与γ-球蛋白等,对治疗结果进行统计分析, 以P <0.05为差异具有显著性界限。结果：两组治疗后ALP、γGT均有改善(P<0.05),治疗组ALT、AST、ALP、γGT、TC、TG下降更明显,差异有统计学意义(P<0.05)；TBIL较治疗前有下降,差异却无统计学意义(P>0.05)；两组患者治疗前后IgM与γ-球蛋白比例相比较,差异均无统计学意义(P >0.05)。结论：对UDCA应答不佳患者,非诺贝特联合UDCA治疗可明显改善患者生化指标,疗效优于单用UDCA治疗。 |
| 英文摘要: |
| [Objective] To observe the clinical effect of fenofibrate combined with ursodeoxycholic acid in the treatment of poor response to ursodeoxycholic acid in primary biliary cholangitis.[Materials and methods] In this study, 24 patients with primary biliary cholangitis who were poor response to ursodeoxycholic acid were treated in our hospital from March 2016 to February 2018,were all cirrhosis compensatory phase.They are randomly divided into treatment group of 15 cases, 15 cases in the control group. The control group continued to give UDCA (German Losan Pharma GmbH pharmaceuticals company), 15 mg/ (kg.d-1), 2-3 oral. The treatment group on the basis of UDCA combined with fenofibrate (French Recipharm Fontaine pharmaceuticals company), 0.16 g/d, and oral. 6 months for a course of treatment. To research and record the laboratory indicators such as AST, ALT, ALP, ALB, TBIL, IgM, gamma globulin, etc.Statistical analysis of the results of treatment, with P<0.05 as the difference has significant boundaries.Results: After treatment, both groups" ALP and γGT have improved (P<0.05), and ALT、AST、ALP、γGT、TC、TG in the treatment group have decreased more significantly, with statistically significant differences (P<0.05).TBIL was decreased before treatment, but the difference was not statistically significant (P>0.05).Compared with the ratio of IgM and γ-globulin before and after treatment, the difference between the two groups was not statistically significant (P >0.05).Conclusion: for UDCA patients with poor response, fenofibrate combined with UDCA treatment can significantly improve patients" biochemical indexes, and the curative effect is better than that of UDCA alone. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
